New Bedford, MA, United States
New Bedford, MA, United States

Time filter

Source Type

Flanders Y.,Jasco Pharmaceuticals LLC | Dumas S.,Jasco Pharmaceuticals LLC | Caserta J.,Jasco Pharmaceuticals LLC | Nicewonger R.,Eisai Inc | And 3 more authors.
Tetrahedron Letters | Year: 2015

Herein, we describe the versatile synthesis of (Z)-5-((2-aminopyrimidin-4-yl)methylene)thiazolidine-2,4-dione inhibitors (1) of the PIM family of kinases. This chemistry strategy was a key element in the multi-variable optimization program with the goal of identifying high quality leads for the development of a treatment for cancer. © 2015 Elsevier Ltd. All rights reserved.


Patent
Jasco Pharmaceuticals LLC | Date: 2012-04-20

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2011-02-17

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1), the TGF pathway and/or the Wnt pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1), the TGF pathway and/or the Wnt pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2010-12-23

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2012-10-24

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK11, CK12, CK13, CK2, Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK11, CK12, CK13, CK2, Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2013-09-20

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2014-12-19

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK11, CK12, CK13, CK2, Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK11, CK12, CK13, CK2, Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.

Loading Jasco Pharmaceuticals LLC collaborators
Loading Jasco Pharmaceuticals LLC collaborators